Evelo Biosciences, Inc.
EVLO
|
$0.3165
-87.39%
710K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-89.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-17.9% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 6,008,068
http://www.evelobio.com
Sec Filling | Patents | 98 employees
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of monoclonal microbials, a modality of oral biologic medicines. It has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
cancer msa treatment
add to watch list Paper trade email alert is off
Press-releases
Carisma Therapeutics Announces Changes to its Board of Directors
Published: 2024-04-01 (Crawled : 11:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.47%
H: 0.23%
C: -0.99%
CRIS | $14.59 -4.14% -4.32% 10K
|
Health Technology
|
| O: 0.7%
H: 16.87%
C: 16.87%
therapeutics
Delisting of Securities of SmileDirectClub, Inc.; Bellerophon Therapeutics, Inc.; Elys Game Technology, Corp.’; Athersys, Inc.; Borqs Technologies, Inc.; ContraFect Corporation; CohBar, Inc.; AgileThought, Inc.; Fat Projects Acquisition Corp.; Evelo Biosciences, Inc.; Troika Media Group, Inc.; Impel Pharmaceuticals Inc.; Fresh Tracks Therapeutics, Inc.; and Near Intelligence, Inc. from The Nasdaq Stock Market
Published: 2023-12-26 (Crawled : 21:00) - globenewswire.com
SDCCQ | $0.0025 -20.0% 150K
|
n/a
|
| O: -28.75%
H: 40.35%
C: 15.79%
NDAQ | $60.35 0.47% 0.46% 3.1M
|
Finance
|
| O: -0.07%
H: 0.75%
C: 0.69%
CWBR | $0.9003 -11.88% 360
|
Health Technology
|
| O: 0.0%
H: 5.11%
C: 5.11%
nasdaq media acquisition pharmaceuticals market
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
Published: 2023-10-17 (Crawled : 11:00) - globenewswire.com
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: -62.87%
H: 55.26%
C: 5.26%
edp2939 psoriasis results study phase 2
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
Published: 2023-08-14 (Crawled : 12:00) - globenewswire.com
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: -4.72%
H: 40.3%
C: 30.71%
business financial results
Global Human Microbiome Therapeutic Market Set to Reach $3.4 Billion by 2030: Unleashing the Potential of Microbiome-based Therapies
Published: 2023-07-18 (Crawled : 02:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.85%
H: 0.75%
C: 0.19%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.0%
H: 1.14%
C: -0.01%
DD | News | $73.89 0.49% 0.0% 2.3M
|
Process Industries
|
| O: 0.7%
H: 2.13%
C: 2.0%
MCRB | $0.5671 -2.93% -3.02% 3.7M
|
Health Technology
|
| O: -0.21%
H: 4.43%
C: 1.48%
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 4.79%
H: 63.71%
C: 54.3%
reach global set potential market
Evelo Biosciences Closes $25.5 Million Private Placement
Published: 2023-07-12 (Crawled : 12:00) - globenewswire.com
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: 2.02%
H: 1.19%
C: -1.05%
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 0.59%
H: 7.09%
C: 3.82%
Evelo Biosciences Announces $25.5 Million Private Placement
Published: 2023-07-10 (Crawled : 12:00) - globenewswire.com
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 8.23%
H: 35.6%
C: 29.2%
Evelo Biosciences Announces Reverse Stock Split Effective
Published: 2023-06-29 (Crawled : 13:00) - globenewswire.com
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: -25.1%
H: 18.46%
C: -7.45%
Cellarity Appoints Dr. Gregory J. Moore to Board of Directors
Published: 2023-06-06 (Crawled : 15:00) - biospace.com/
OLK | News | $21.85 -1.89% -1.92% 590K
|
Manufacturing
|
| O: 0.25%
H: 4.64%
C: 1.33%
OMGA | $2.4 -0.83% -0.83% 400K
|
|
| O: -1.19%
H: 9.8%
C: 4.7%
SANA | $7.605 -1.62% -1.64% 3.4M
|
|
| O: 0.48%
H: 3.68%
C: 1.44%
DVA | $127.82 1.36% 0.0% 490K
|
Health Services
|
| O: 0.02%
H: 0.83%
C: 0.1%
MCRB | $0.5671 -2.93% -3.02% 3.7M
|
Health Technology
|
| O: -0.21%
H: 3.17%
C: 0.63%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 0.08%
H: 0.12%
C: -1.63%
FHTX | $5.335 -3.53% -3.66% 120K
|
Health Technology
|
| O: 1.24%
H: 2.85%
C: 0.68%
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 6.9%
H: 0.81%
C: 0.73%
DNLI | $15.98 -3.74% -3.88% 1.5M
|
Health Technology
|
| O: 0.16%
H: 1.47%
C: 0.23%
moore
Alltrna Engineers tRNA Oligonucleotide with Improved Potency and Activity for In Vivo Readthrough of Premature Termination Codons
Published: 2023-05-18 (Crawled : 13:20) - biospace.com/
OMGA | $2.4 -0.83% -0.83% 400K
|
|
| O: 0.0%
H: 0.65%
C: -4.35%
SANA | $7.605 -1.62% -1.64% 3.4M
|
|
| O: -1.87%
H: 2.72%
C: -1.63%
MCRB | $0.5671 -2.93% -3.02% 3.7M
|
Health Technology
|
| O: 0.61%
H: 0.0%
C: -2.82%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 0.28%
H: 0.07%
C: -0.47%
FHTX | $5.335 -3.53% -3.66% 120K
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: -0.15%
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 8.57%
H: 1.97%
C: -1.32%
DNLI | $15.98 -3.74% -3.88% 1.5M
|
Health Technology
|
| O: -0.3%
H: 2.6%
C: 2.36%
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10